Agree about the need for big $$$. If you read the SEC filing, Sanofi keeps all the cash and receivables, ASTM has to buy support services, Denmark is not profitable without significant corporate support (so the money there isn't going to help much), ASTM takes on 100% of severance costs, and have to assume Sanofi sold the business (for virtually nothing) to get out from under on-going losses. This is on top of the on-going cash needed for the existing ASTM programs. How does all of this add up? Would be great if someone could ask at the meeting.